医学
内科学
癌胚抗原
多元分析
结直肠癌
肿瘤科
置信区间
突变
胃肠病学
临床终点
淋巴结
生存分析
队列
临床试验
癌症
基因
生物化学
化学
作者
Kristoffer Watten Brudvik,Robert Jones,Felice Giuliante,Junichi Shindoh,Guillaume Passot,Michael Chung,Juhee Song,Liang Li,Vegar Johansen Dagenborg,Åsmund Avdem Fretland,Bård I. Røsok,Agostino Maria De Rose,Francesco Ardito,Bjørn Edwin,Elena Panettieri,Luigi Maria Larocca,Satoshi Yamashita,Claudius Conrad,Thomas A. Aloia,Graeme J. Poston,Bjørn Atle Bjørnbeth,Jean Nicolas Vauthey
出处
期刊:Annals of Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2019-01-01
卷期号:269 (1): 120-126
被引量:161
标识
DOI:10.1097/sla.0000000000002319
摘要
Objective: To determine the impact of RAS mutation status on the traditional clinical score (t-CS) to predict survival after resection of colorectal liver metastases (CLM). Background: The t-CS relies on the following factors: primary tumor nodal status, disease-free interval, number and size of CLM, and carcinoembryonic antigen level. We hypothesized that the addition of RAS mutation status could create a modified clinical score (m-CS) that would outperform the t-CS. Methods: Patients who underwent resection of CLM from 2005 through 2013 and had RAS mutation status and t-CS factors available were included. Multivariate analysis was used to identify prognostic factors to include in the m-CS. Log-rank survival analyses were used to compare the t-CS and the m-CS. The m-CS was validated in an international multicenter cohort of 608 patients. Results: A total of 564 patients were eligible for analysis. RAS mutation was detected in 205 (36.3%) of patients. On multivariate analysis, RAS mutation was associated with poor overall survival, as were positive primary tumor lymph node status and diameter of the largest liver metastasis >50 mm. Each factor was assigned 1 point to produce a m-CS. The m-CS accurately stratified patients by overall and recurrence-free survival in both the initial patient series and validation cohort, whereas the t-CS did not. Conclusions: Modifying the t-CS by replacing disease-free interval, number of metastases, and CEA level with RAS mutation status produced an m-CS that outperformed the t-CS. The m-CS is therefore a simple validated tool that predicts survival after resection of CLM.
科研通智能强力驱动
Strongly Powered by AbleSci AI